Trial · NCT02597712
Results by group27
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 27
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Ki67 Biomarker Expression | Treatment | Baseline | 1539 | Standard Deviation 514 | cells/mm^2 |
| Change in Ki67 Biomarker Expression | YF476 Placebo | Baseline | 1556 | Standard Deviation 622 | cells/mm^2 |
| Change in Ki67 Biomarker Expression | Treatment | Week 12 | 1575 | Standard Deviation 620.7 | cells/mm^2 |
| Change in Ki67 Biomarker Expression | YF476 Placebo | Week 12 | 1864 | Standard Deviation 640.3 | cells/mm^2 |
| Expression of Biomarkers Potentially Associated With Esophageal Adenocarcinoma (EAC) | Treatment | CCK2R, Week 12 | -1.19 | relative log-fold change | |
| Expression of Biomarkers Potentially Associated With Esophageal Adenocarcinoma (EAC) | Treatment | PTGS2, Week 12 | 0.31 | relative log-fold change | |
| Expression of Biomarkers Potentially Associated With Esophageal Adenocarcinoma (EAC) | Treatment | DCLK1, Week 12 | -0.34 | relative log-fold change | |
| Abundance of Biomarkers of Gastric Acid Suppression | Treatment | Week 4 | 242.6 | Standard Deviation 142.3 | pmol/L |
| Abundance of Biomarkers of Gastric Acid Suppression | YF476 Placebo | Week 4 | 43.6 | Standard Deviation 9.9 | pmol/L |
| Abundance of Biomarkers of Gastric Acid Suppression | Treatment | Week 6 | 103.3 | Standard Deviation 89.9 | pmol/L |
| Abundance of Biomarkers of Gastric Acid Suppression | YF476 Placebo | Week 6 | 63.9 | Standard Deviation 32.2 | pmol/L |
| Abundance of Biomarkers of Gastric Acid Suppression | Treatment | Week 8 | 234.3 | Standard Deviation 156.5 | pmol/L |
| Abundance of Biomarkers of Gastric Acid Suppression | YF476 Placebo | Week 8 | 96.4 | Standard Deviation 54.2 | pmol/L |
| Abundance of Biomarkers of Gastric Acid Suppression | Treatment | Week 12 | 146.8 | Standard Deviation 112.8 | pmol/L |
| Abundance of Biomarkers of Gastric Acid Suppression | YF476 Placebo | Week 12 | 49.2 | Standard Deviation 20.4 | pmol/L |
| Abundance of Biomarkers of Gastric Acid Suppression | Treatment | Follow-up | 94.9 | Standard Deviation 78.8 | pmol/L |
| Abundance of Biomarkers of Gastric Acid Suppression | YF476 Placebo | Follow-up | 64.7 | Standard Deviation 37.7 | pmol/L |
| Abundance of Biomarkers of ECL Cell Hyperplasia | Treatment | Week 4 | 3.9 | Standard Deviation 1.8 | nmol/L |
| Abundance of Biomarkers of ECL Cell Hyperplasia | YF476 Placebo | Week 4 | 8.8 | Standard Deviation 3.7 | nmol/L |
| Abundance of Biomarkers of ECL Cell Hyperplasia | Treatment | Week 6 | 1.8 | Standard Deviation 0.9 | nmol/L |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02597712/results